10 results
PRE 14A
AKRO
Akero Therapeutics Inc
16 Apr 24
Preliminary proxy
4:30pm
by our audit committee or the engagement is entered into pursuant to the pre-approval procedure described below.
From time to time, our audit committee … committee has assessed the independence of Pearl Meyer consistent with Nasdaq listing standards and has concluded that the engagement does not raise any
8-K
EX-99.1
AKRO
Akero Therapeutics Inc
18 Dec 23
Akero Therapeutics Announces First Patients Dosed in Efruxifermin Phase 3 SYNCHRONY Program
7:08am
and are delighted with the current level of engagement by clinicians and patients,” said Kitty Yale, chief development officer of Akero. “We look forward
DEF 14A
86d9k7m6 obe
27 Apr 20
Definitive proxy
7:30am
S-1
EX-10.4
wa35nt yy6c
24 May 19
IPO registration
4:18pm
- Prev
- 1
- Next